Deutsche Bank AG Acquires Shares of 93,844 IDEAYA Biosciences, Inc. $IDYA

Deutsche Bank AG bought a new stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 93,844 shares of the company’s stock, valued at approximately $3,498,000.

A number of other institutional investors and hedge funds have also modified their holdings of the stock. GSK plc purchased a new position in IDEAYA Biosciences in the 4th quarter valued at about $46,093,000. State Street Corp increased its position in shares of IDEAYA Biosciences by 27.6% during the fourth quarter. State Street Corp now owns 4,134,641 shares of the company’s stock worth $142,935,000 after purchasing an additional 893,707 shares in the last quarter. Janus Henderson Group PLC increased its position in shares of IDEAYA Biosciences by 11.8% during the fourth quarter. Janus Henderson Group PLC now owns 7,186,456 shares of the company’s stock worth $248,344,000 after purchasing an additional 758,117 shares in the last quarter. First Turn Management LLC acquired a new position in IDEAYA Biosciences in the 4th quarter valued at $25,017,000. Finally, Fiera Capital Corp raised its stake in IDEAYA Biosciences by 32.6% in the 4th quarter. Fiera Capital Corp now owns 2,437,262 shares of the company’s stock valued at $84,256,000 after purchasing an additional 599,295 shares during the last quarter. Hedge funds and other institutional investors own 98.29% of the company’s stock.

Insider Transactions at IDEAYA Biosciences

In other IDEAYA Biosciences news, CAO Briseno Andres Ruiz sold 9,550 shares of IDEAYA Biosciences stock in a transaction that occurred on Tuesday, July 7th. The stock was sold at an average price of $40.01, for a total value of $382,095.50. Following the sale, the chief accounting officer owned 26,466 shares of the company’s stock, valued at approximately $1,058,904.66. The trade was a 26.52% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 4.70% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several equities research analysts have issued reports on IDYA shares. Royal Bank Of Canada lowered their target price on shares of IDEAYA Biosciences from $53.00 to $48.00 and set an “outperform” rating on the stock in a research note on Tuesday, July 7th. Wall Street Zen cut shares of IDEAYA Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Truist Financial decreased their target price on shares of IDEAYA Biosciences from $63.00 to $59.00 and set a “buy” rating on the stock in a research note on Wednesday, August 5th. Mizuho cut their price target on IDEAYA Biosciences from $52.00 to $50.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of IDEAYA Biosciences in a report on Friday, May 22nd. Fourteen investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, IDEAYA Biosciences has a consensus rating of “Moderate Buy” and a consensus target price of $50.12.

IDEAYA Biosciences Price Performance

Shares of NASDAQ IDYA opened at $41.58 on Thursday. The company has a market capitalization of $3.65 billion, a P/E ratio of -21.43 and a beta of -0.10. The company has a 50 day simple moving average of $36.78 and a 200-day simple moving average of $33.05. IDEAYA Biosciences, Inc. has a 1 year low of $23.23 and a 1 year high of $42.68.

IDEAYA Biosciences (NASDAQ:IDYA) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($1.22) earnings per share for the quarter, missing the consensus estimate of ($1.06) by ($0.16). IDEAYA Biosciences had a negative return on equity of 16.73% and a negative net margin of 75.93%.The business had revenue of $8.86 million during the quarter, compared to analysts’ expectations of $8.02 million. During the same quarter in the previous year, the company posted ($0.88) earnings per share. The company’s revenue was up 8800.0% on a year-over-year basis. As a group, research analysts expect that IDEAYA Biosciences, Inc. will post -4.38 EPS for the current year.

IDEAYA Biosciences Profile

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.